Abstract 1218P
Background
Cancer is considered a leading cause of mortality and morbidity worldwide. This study constitutes one part of the user requirement definition of INCISIVE EU project. The project has been designed to explore the full potential of artificial intelligence (AI)-based technologies in cancer imaging. The study aimed to map cancer care pathways (breast, prostate, colorectal and lung cancers) across INCISIVE partner countries, and identify obstacles within these pathways.
Methods
A qualitative research approach employing email interviews was used. A purposive sampling strategy was employed to recruit ten oncology specialised healthcare professionals from INCISIVE partner countries: Greece, Cyprus, Spain, Italy, Finland, United Kingdom (UK) and Serbia. Data was collected between December 2020 and April 2021. Data was entered into Microsoft Excel spreadsheet to allow content and comparative analysis. Appropriate ethical approval was obtained for this study.
Results
Delays in the diagnosis and treatment of cancer was evident from all the pathways studied. With the exception of the UK, none of the countries studied had official national data regarding delays in cancer diagnosis and treatment. There was a considerable variation in the availability of imaging and diagnostic services across the seven countries that were analysed. Several concerns were also noted for national screening for the four investigated cancer types.
Conclusions
Delays in the diagnosis and treatment of cancer remain challenging issues that need to be addressed. To effectively address these challenges, it is crucial to have a systematic reporting of diagnostic and therapeutic delays in all countries. Proper estimation of the magnitude of the problem is essential, as no problem can be effectively tackled without an accurate understanding of its magnitude. Our findings also support the orientation of the current policies towards early detection and wide scale adoption and implementation of cancer screening, through research, innovation, and technology. Technologies involving AI can have a great potential to revolutionise cancer care delivery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
INCISIVE Consortium.
Funding
EU Horizion 2020.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1241P - Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics
Presenter: Kai He
Session: Poster session 14
1242P - Implementing functional precision oncology in real-world patients: Translating extensive in vitro data into personalized treatment combining genetics and functional assays
Presenter: Dörthe Schaffrin-Nabe
Session: Poster session 14
1243P - Ocular surface squamous neoplasia early diagnosis using an AI-empowered autofluorescence multispectral imaging technique
Presenter: Abbas HABIBALAHI
Session: Poster session 14
1244P - AI-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners
Presenter: Ramona Erber
Session: Poster session 14
1245P - A lymph nodal staging assessment model for various histologic types of small intestinal tumors
Presenter: YOUSHENG LI
Session: Poster session 14
1246P - Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
Presenter: Juan Blanco Heredia
Session: Poster session 14
1247P - A detection model for EGFR mutations in lung adenocarcinoma patients based on volatile organic compounds
Presenter: Yunpeng Yang
Session: Poster session 14
1248P - Development of a high performance and noninvasive diagnostic model using blood cell-free microRNAs for multi-cancer early detection
Presenter: Jason Zhang
Session: Poster session 14
1249P - Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data
Presenter: Jeffrey van Putten
Session: Poster session 14
1250P - Assessing lung carcinoma: A retrospective study on volume evaluation, consolidation and infiltration using chest OMX
Presenter: Swarnambiga Ayyachamy
Session: Poster session 14